이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ABVC BioPharma 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Uttam Patil

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.7%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	5.3yrs

최근 관리 업데이트

Recent updates

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

Mar 13

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Oct 05

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

Sep 23

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Aug 18

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

Aug 17

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

Jul 13

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

Jun 30

CEO

Uttam Patil (38 yo)

less than a year

테뉴어

Dr. Uttam Yashwant Patil, Ph D., is Chief Executive Officer of ABVC BioPharma, Inc. from June 21, 2023. Dr. Patil has served as the Chief Operating and Scientific Officer of the BioKey, Inc. since May 2023...

리더십 팀

이름	위치	테뉴어	보상	소유권
Eugene Jiang	Chairman & Chief Business Officer	8.9yrs	US$200.00k	9.23% $ 734.1k
Uttam Patil	Chief Executive Officer	less than a year	데이터 없음	0.67% $ 53.2k
Leeds Chow	CFO & Principal Accounting Officer	1.8yrs	US$180.00k	0.48% $ 38.2k
Tsung-Shann Jiang	Chief Scientific Officer	less than a year	US$200.00k	4.01% $ 319.4k

1.0yrs

평균 재임 기간

38yo

평균 연령

경험이 풍부한 관리: ABVC 의 관리팀은 경험 (평균 재직 기간 1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Eugene Jiang	Chairman & Chief Business Officer	8.9yrs	US$200.00k	9.23% $ 734.1k
Tsung-Shann Jiang	Chief Scientific Officer	5.3yrs	US$200.00k	4.01% $ 319.4k
Tsang Ming Jiang	Director	6.6yrs	데이터 없음	0.39% $ 30.9k
Norimi Sakamoto	Independent Director	6.6yrs	데이터 없음	0.39% $ 30.8k
Yen-Hsin Chou	Independent Director	6.6yrs	데이터 없음	0.39% $ 30.8k
Yoshinobu Odaira	Independent Director	5.3yrs	데이터 없음	0.53% $ 42.5k
Susanna Cunningham-Rundles	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Chang-Jen Jiang	Director	6.6yrs	데이터 없음	0.39% $ 30.8k
Che-Wei Hsu	Independent Director	2.1yrs	데이터 없음	0.39% $ 30.7k
Shuling Jiang	Director	2.1yrs	데이터 없음	8.06% $ 641.3k
Hsin-Hui Miao	Independent Director	2yrs	데이터 없음	0.44% $ 35.3k
Yu-Min Chung	Independent Director	1.9yrs	데이터 없음	0.39% $ 30.8k

5.3yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: ABVC 의 이사회는 경험(평균 재직 기간 5.3 년)으로 간주됩니다.

ABVC BioPharma 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer

Less than half of directors are independent

ABVC BioPharma, Inc. Announces Board Changes

Recent updates

ABVC BioPharma, Inc. announced delayed 10-Q filing

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma, Inc. announced delayed 10-Q filing

Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study

ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $1.75 million.

ABVC BioPharma, Inc. announced that it expects to receive $1.75 million in funding

Nasdaq Grants ABVC Biopharma an Extension to Comply with Listing Rule 5550(b)(1)

ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer

ABVC BioPharma Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders' Equity Requirement

ABVC BioPharma, Inc. Announces Vitargus®? Phase II Study Receives Ethical Approval At Sydney Eye Hospital in Australia

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.20 loss in 1Q 2022)

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

ABVC BioPharma Receives an Additional 180 Days, Until August 14, 2023, to Comply with Rule 5550(a)(2)

Abvc Biopharma Abv-1505 Adhd Phase Iia Results Presented At 2023 Apsard Conference

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

ABVC BioPharma, Inc. Receives Thai FDA Approval for Phase II Vitargus Study Protocol

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder

ABVC BioPharma, Inc. Announces That Cedars-Sinai Medical Center Institutional Review Board (IRB) Approves Institution Joining the Phase I Study of ABV-1601

ABVC BioPharma, Inc. Announces Vitargus(R) Phase II Study Plan Approved by Hrec in Australia

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Abvc Biopharma, Inc. Provides Adhd Phase Ii Part 2 Clinical Study Update and Announces Ucsf Institutional Review Board Approval

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

ABVC BioPharma Receives Non-Compliance Letter from Nasdaq

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma, Inc. Announces Board Changes

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

ABVC BioPharma, Inc. Announces the Vitargus® Phase II Clinical Study Protocol Approval by the Central Research Ethics Committee (CREC) of the National Research Council of Thailand

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

ABVC BioPharma, Inc. Submitts Vitargus(R) Phase II Study Plan to Australia HREC

Abvc Biopharma, Inc. Appoints Ms. Hsin-Hui Miao to its Board

ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study

ABVC BioPharma, Inc. Announces Board Elections

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $4.22 million.

ABVC BioPharma, Inc. Announces ADHD Phase II Part 2 Clinical Study First Subject

ABVC Biopharma Announces Streamlined Vitargus® Manufacturing Process

Insufficient new directors

ABVC BioPharma, Inc. Announces Vitargus Phase II Clinical Study Investigator Meeting

Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

ABVC BioPharma, Inc. Selects Additional Vitargus Phase II Study Sites

Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?

High number of new directors

Third quarter 2021 earnings released: US$0.067 loss per share (vs US$0.095 loss in 3Q 2020)

High number of new directors

High number of new directors

High number of new directors

ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study

High number of new directors

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Second quarter 2021 earnings released: US$0.081 loss per share (vs US$0.095 loss in 2Q 2020)

High number of new directors

ABVC BioPharma, Inc. has completed a Composite Units Offering in the amount of $6.875 million.